Biotech Acquisition Company (BIOT) Terminates Blade Deal
by Marlena Haddad on 2022-06-13 at 8:52am

Biotech Acquisition Company (NASDAQ:BIOT) announced this morning that it has mutually terminated its combination agreement with biopharmaceutical firm Blade Therapeutics.

Although the parties did not disclose the reason for the deal termination, it is likely due to unfavorable market conditions or difficulty satisfying closing conditions. But, with a deadline of January 28, 2023, the SPAC intends to continue in its efforts to identify a prospective target business for an initial business combination.

The news comes shortly after BIOT postponed its special meeting on June 3 for a second time. This meeting was first pushed back from June 1 and as with the previous postponement, Biotech noted that it had obtained sufficient votes to approve the transaction, but it needed additional time to satisfy all closing conditions. As required by Cayman Islands law, BIOT will convene the previously postponed extraordinary general meeting of shareholders tomorrow, Tuesday, June 14, 2022, at 9:00 AM Eastern Time, but intends to adjourn.

Biotech was required to maintain at least $75 million in cash available through its trust and PIPE proceeds in order for the deal to close. It initially announced a $24.3 million PIPE and signed a common stock purchase agreement on May 9 with an affiliate of Cantor Fitzgerald for it to purchase up to $75 million in the combined company’s shares post-close.

The current market pain is still creating challenging conditions for SPACs and IPOs alike, making BIOT’s deal the 24th to terminate this year. Biotech Acquisition Company initially raised $230 million in its initial public offering in January 2021, and will remain committed to finding a life-sciences partner that can deliver value for its shareholders. The SPAC is led by CEO and Chairman Dr. Michael Shleifer.

As for Blade, it will remain focused on its development plans, particularly for its differentiated lead asset, cudetaxestat, a non-competitive autotaxin inhibitor which is expected to enter a planned phase 2 clinical study in patients with idiopathic pulmonary fibrosis. Earlier this year, Blade announced that the FDA provided the feedback necessary in order for it to proceed to Phase II proof of concept and dose-ranging studies for its cudetaxestat drug candidate.

Biotech Acquisition Company initially announced its $352.8 million combination with Blade last year on November 8, 2021. San Francisco-based Blade Therapeutics is developing three drug candidates as potential therapies against varying forms of organ fibrosis with its most advanced having completed Phase I.

 

Recent Posts
by Nicholas Alan Clayton on 2024-07-26 at 8:13am

At the SPAC of Dawn As a rough week in the market comes to a close, at least one de-SPAC has some cause to show off. Many fashion brands were among the hard hit in recent days and not simply for macro reasons. Luis Vuitton-owner LVMH (PA:MC) dropped this week after an earnings miss led...

by Kristi Marvin on 2024-07-25 at 10:05am

Shepherd Ave Capital Acquisition Corp. (Nasdaq: SPHAU) is the latest SPAC to file to IPO, making 24 new registration statements that have filed since June 1, 2024. So far, only two of those 24 have gone public, but it does indicate an active August.  In SPACLand at least, August is never slow. As for Shepherd...

by Nicholas Alan Clayton on 2024-07-25 at 8:05am

At the SPAC of Dawn SPACs have now priced 20 IPOs seven months into 2024 with an eye on beating 2023’s total of 31 IPOs. With a little more than 5 months left in the year, it’s expected that SPACs should at least match that number by only needing to price roughly two IPOs per...

by Nicholas Alan Clayton on 2024-07-25 at 6:14am

DT Cloud Star announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “DTSQU”, Thursday, July 25, 2024. The new SPAC aims to combine with an established business with long-term financial visibility, but has not limited itself to a particular industry or sector....

by Nicholas Alan Clayton on 2024-07-24 at 4:38pm

Launch Two (NASDAQ:LPBBU) has filed for a $200 million IPO that shows how the market has shifted for new issuance since its sister SPAC Launch One (NASDAQ:LPAAU) filed just over a month ago. Both SPACs are underwritten by Cantor Fitzgerald and seeking nominally the same raise at IPO, but Launch Two is overfunding its trust...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved